contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


the-nomination-committees-proposal-for-the-board-of-arocell-for-the-annual-general-meeting-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.

AroCell

The Nomination Committee proposes the election of Max Pihlqvist as the Chairman of the Board, and the election of Fredrik Lindgren as a new board member for AroCells Board of Directors at the...

<div class="mfn-preamble"><p><strong>The Nomination Committee proposes the election of Max Pihlqvist as the Chairman of the Board, and the election of Fredrik Lindgren as a new board member for AroCells Board of Directors at the 2024 Annual General Meeting.</strong></p></div><div class="mfn-body"><p>Fredrik Lindgren has over 25 years of experience in the Life Science sector, where he has served as a CEO or board member in more than 10 different companies. He served as the Managing Director at Larodan AB until 2023, and previously, he held the role as CEO at Karo Pharma AB and Biolin Scientific AB. Fredrik holds a law degree from Lund University and an eMBA from Stockholm School of Business.</p><p>The nomination committee´s proposal for the board at the AGM is the re-election of Eva Nordström, Agneta Tufvesson Alm, Clas Runnberg, and Max Pihlqvist, and the new election of Fredrik Lindgren.</p><p>The Nomination Committee proposes the new election of Max Pihlqvist as the Chairman of the Board.</p><p>AroCells Nomination Committee consists of:<br>Christian Lindgren (Chairman)<br>Clas Runnberg<br>Jon Eiken</p></div><div class="mfn-footer mfn-contacts mfn-d7431fd42f58"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Anders Hultman, CEO<br>Phone: +46 (0) 8 799 67 50<br>E-mail:&nbsp;<a rel="noopener" href="mailto:anders.hultman@arocell.com">anders.hultman@arocell.com</a></p></div><div class="mfn-footer mfn-about mfn-3400a8a23fe3"><p><strong class="mfn-heading-1">About AroCell</strong></p><hr><p>AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; <a rel="noopener" href="https://arocell.us12.list-manage.com/track/click?u=afc00720b3f14956d7aa211ee&amp;id=b0c0db8833&amp;e=1eac5f4714">www.arocell.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-12 12:30 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/69b5bd82-b1b2-430b-a975-f76d46b7fde7/the-nomination-committees-proposal-for-the-board-of-arocell-for-the-annual-general-meeting-2024.pdf" class="mfn-generated mfn-primary">The nomination committee's proposal for the board of AroCell for the Annual General Meeting 2024</a></p></div>

The nomination committee's proposal for the board of AroCell for the Annual General Meeting 2024

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

Helsinki Stock Exchange is cheap

Valuation methods: Valuation multiples

Stay up to date with our newsletter